Multiple Myeloma - VJHemOnc

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

ASH press briefing rundown: new drugs and targets

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

VJSocial Media Masterclass – Social Media Strategy

Learn how to build a social media strategy effectively and appropriately alongside your clinical practice. Independent medical support by Janssen…

VJSocial Media Masterclass – Engagement on Twitter

Learn how to engage on Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…

DETERMINATION: the addition of ASCT to lenalidomide, bortezomib, and dexamethasone provides a PFS advantage for patients with newly diagnosed multiple myeloma

For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…

Amyloidosis: current challenges and future outlooks

VJHemOnc is excited to bring you a feature covering current challenges and future outlooks in amyloidosis.

Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

The U.S. Food and Drug Administration (FDA) has approved the use of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed chimeric antigen receptor…

Highlights from the EBMT-EHA CAR T-cell 2022 Meeting

VJHemOnc is excited to bring you the latest research updates in CAR-T therapy from the EBMT-EHA 4th European CAR T-cell…

VJSocial Media Masterclass

Learn how to use Twitter alongside your clinical practice from leading hematology experts. Independent medical support by Janssen Pharmaceuticals

IMW 2021: Heinz Ludwig and Hermann Einsele discuss meeting highlights

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

IMW 2021: myeloma updates with Maria-Victoria Mateos and Irene Ghobrial

VJHemOnc is excited to bring insights from Maria Victoria-Mateos and Irene Ghobrial, as discussed at the 18th International Myeloma Workshop…

Key trial updates from IMW 2021

VJHemOnc is excited to bring you the latest updates from 18th International Myeloma Workshop (IMW) 2021, which brought together leading…

EHA 2021: updates in myeloid malignancies

VJHemOnc is excited to bring you the latest updates from research investigating the treatment and management of myeloid malignancies, as…

Highlights from the EBMT 2021 virtual meeting

VJHemOnc is excited to bring you highlights from the 47th Annual Meeting of the European Group for Blood and Marrow…

Homozygous BCMA deletion in response to ide-cel in myeloma patient

Immunological approaches to the treatment of multiple myeloma have rapidly evolved in recent years. One of the most promising fields…

features: Multiple Myeloma